Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Anthranilic amide and imidazobenzothiadiazole compounds disrupt Mycobacterium tuberculosis membrane potential.

Smith J, Wescott H, Early J, Mullen S, Guzman J, Odingo J, Lamar J, Parish T.

Medchemcomm. 2019 May 3;10(6):934-945. doi: 10.1039/c9md00088g. eCollection 2019 Jun 1.

PMID:
31303991
2.

8-Hydroxyquinolines are bactericidal against Mycobacterium tuberculosis.

Odingo JO, Early JV, Smith J, Johnson J, Bailey MA, Files M, Guzman J, Ollinger J, Korkegian A, Kumar A, Ovechkina Y, Parish T.

Drug Dev Res. 2019 Aug;80(5):566-572. doi: 10.1002/ddr.21531. Epub 2019 Mar 20.

PMID:
30893501
3.

In Vitro Evaluation of Novel Nitazoxanide Derivatives against Mycobacterium tuberculosis.

Odingo J, Bailey MA, Files M, Early JV, Alling T, Dennison D, Bowman J, Dalai S, Kumar N, Cramer J, Masquelin T, Hipskind PA, Parish T.

ACS Omega. 2017 Sep 30;2(9):5873-5890. doi: 10.1021/acsomega.7b00892. Epub 2017 Sep 18.

4.

Identification of cyclic hexapeptides natural products with inhibitory potency against Mycobacterium tuberculosis.

Singh SB, Odingo J, Bailey MA, Sunde B, Korkegian A, O'Malley T, Ovechkina Y, Ioerger TR, Sacchettini JC, Young K, Olsen DB, Parish T.

BMC Res Notes. 2018 Jun 28;11(1):416. doi: 10.1186/s13104-018-3526-z.

5.

Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.

Cleghorn LAT, Ray PC, Odingo J, Kumar A, Wescott H, Korkegian A, Masquelin T, Lopez Moure A, Wilson C, Davis S, Huggett M, Turner P, Smith A, Epemolu O, Zuccotto F, Riley J, Scullion P, Shishikura Y, Ferguson L, Rullas J, Guijarro L, Read KD, Green SR, Hipskind P, Parish T, Wyatt PG.

J Med Chem. 2018 Aug 9;61(15):6592-6608. doi: 10.1021/acs.jmedchem.8b00172. Epub 2018 Jul 26.

6.

Synthesis and biological evaluation of aryl-oxadiazoles as inhibitors of Mycobacterium tuberculosis.

Martinez-Grau MA, Valcarcel ICG, Early JV, Gessner RK, de Melo CS, de la Nava EMM, Korkegian A, Ovechkina Y, Flint L, Gravelle A, Cramer JW, Desai PV, Street LJ, Odingo J, Masquelin T, Chibale K, Parish T.

Bioorg Med Chem Lett. 2018 Jun 1;28(10):1758-1764. doi: 10.1016/j.bmcl.2018.04.028. Epub 2018 Apr 13.

7.

Improved Phenoxyalkylbenzimidazoles with Activity against Mycobacterium tuberculosis Appear to Target QcrB.

Chandrasekera NS, Berube BJ, Shetye G, Chettiar S, O'Malley T, Manning A, Flint L, Awasthi D, Ioerger TR, Sacchettini J, Masquelin T, Hipskind PA, Odingo J, Parish T.

ACS Infect Dis. 2017 Dec 8;3(12):898-916. doi: 10.1021/acsinfecdis.7b00112. Epub 2017 Oct 31.

8.

The synthesis and evaluation of triazolopyrimidines as anti-tubercular agents.

Zuniga ES, Korkegian A, Mullen S, Hembre EJ, Ornstein PL, Cortez G, Biswas K, Kumar N, Cramer J, Masquelin T, Hipskind PA, Odingo J, Parish T.

Bioorg Med Chem. 2017 Aug 1;25(15):3922-3946. doi: 10.1016/j.bmc.2017.05.030. Epub 2017 May 19.

9.

Synthesis and Evaluation of the 2-Aminothiazoles as Anti-Tubercular Agents.

Kesicki EA, Bailey MA, Ovechkina Y, Early JV, Alling T, Bowman J, Zuniga ES, Dalai S, Kumar N, Masquelin T, Hipskind PA, Odingo JO, Parish T.

PLoS One. 2016 May 12;11(5):e0155209. doi: 10.1371/journal.pone.0155209. eCollection 2016.

10.

Synergy between Colistin and the Signal Peptidase Inhibitor MD3 Is Dependent on the Mechanism of Colistin Resistance in Acinetobacter baumannii.

Martínez-Guitián M, Vázquez-Ucha JC, Odingo J, Parish T, Poza M, Waite RD, Bou G, Wareham DW, Beceiro A.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4375-9. doi: 10.1128/AAC.00510-16. Print 2016 Jul.

11.

Identification of Phenoxyalkylbenzimidazoles with Antitubercular Activity.

Chandrasekera NS, Alling T, Bailey MA, Files M, Early JV, Ollinger J, Ovechkina Y, Masquelin T, Desai PV, Cramer JW, Hipskind PA, Odingo JO, Parish T.

J Med Chem. 2015 Sep 24;58(18):7273-85. doi: 10.1021/acs.jmedchem.5b00546. Epub 2015 Sep 2.

PMID:
26295286
12.

The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity.

Chandrasekera NS, Alling T, Bailey M, Korkegian A, Ahn J, Ovechkina Y, Odingo J, Parish T.

J Negat Results Biomed. 2015 Feb 13;14:4. doi: 10.1186/s12952-015-0024-x.

13.

Synthesis and evaluation of the 2,4-diaminoquinazoline series as anti-tubercular agents.

Odingo J, O'Malley T, Kesicki EA, Alling T, Bailey MA, Early J, Ollinger J, Dalai S, Kumar N, Singh RV, Hipskind PA, Cramer JW, Ioerger T, Sacchettini J, Vickers R, Parish T.

Bioorg Med Chem. 2014 Dec 15;22(24):6965-79. doi: 10.1016/j.bmc.2014.10.007. Epub 2014 Oct 22.

14.

Synthesis and anti-tubercular activity of 3-substituted benzo[b]thiophene-1,1-dioxides.

Chandrasekera NS, Bailey MA, Files M, Alling T, Florio SK, Ollinger J, Odingo JO, Parish T.

PeerJ. 2014 Oct 7;2:e612. doi: 10.7717/peerj.612. eCollection 2014.

15.

A high-throughput screen against pantothenate synthetase (PanC) identifies 3-biphenyl-4-cyanopyrrole-2-carboxylic acids as a new class of inhibitor with activity against Mycobacterium tuberculosis.

Kumar A, Casey A, Odingo J, Kesicki EA, Abrahams G, Vieth M, Masquelin T, Mizrahi V, Hipskind PA, Sherman DR, Parish T.

PLoS One. 2013 Nov 7;8(11):e72786. doi: 10.1371/journal.pone.0072786. eCollection 2013.

16.

Inhibition of the sole type I signal peptidase of Mycobacterium tuberculosis is bactericidal under replicating and nonreplicating conditions.

Ollinger J, O'Malley T, Ahn J, Odingo J, Parish T.

J Bacteriol. 2012 May;194(10):2614-9. doi: 10.1128/JB.00224-12. Epub 2012 Mar 16.

17.

Validation of the essential ClpP protease in Mycobacterium tuberculosis as a novel drug target.

Ollinger J, O'Malley T, Kesicki EA, Odingo J, Parish T.

J Bacteriol. 2012 Feb;194(3):663-8. doi: 10.1128/JB.06142-11. Epub 2011 Nov 28.

18.

Discovery and SAR of trisubstituted thiazolidinones as CCR4 antagonists.

Allen S, Newhouse B, Anderson AS, Fauber B, Allen A, Chantry D, Eberhardt C, Odingo J, Burgess LE.

Bioorg Med Chem Lett. 2004 Apr 5;14(7):1619-24.

PMID:
15026036

Supplemental Content

Loading ...
Support Center